The generic name for Dupixent is dupilumab [1].
What is Dupixent used to treat?
Dupixent (dupilumab) is a prescription medication approved to treat moderate-to-severe atopic dermatitis in patients 6 months of age and older whose disease is not controlled with topical therapies or when those therapies are not advisable. It is also used for moderate-to-severe asthma in patients aged 6 years and older whose asthma is not controlled with their current asthma medications, and as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyposis (CRSwNP) in adult patients whose disease is not controlled with nasal corticosteroids. Additionally, it is indicated for eosinophilic esophagitis (EoE) in patients 12 years of age and older, weighing 88 pounds (40 kg) or more, who have esophageal stricturing at biopsy, or who have difficulty swallowing despite maximal recommended dosing of an all FDA-approved EoE drug and have had one or more swallowing episodes in the past 12 months. Dupixent is also used for the treatment of prurigo nodularis (PN) in patients 18 years of age and older [1].
How does dupilumab work?
Dupilumab is a monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha (IL-4Rα) pathway [1]. This pathway is a key driver of inflammation in conditions like atopic dermatitis, asthma, CRSwNP, EoE, and PN [1]. By blocking the signaling of IL-4 and IL-13, dupilumab helps to reduce inflammation and improve symptoms associated with these diseases [1].
When is Dupixent's patent expected to expire?
Information regarding specific patent expiry dates for Dupixent is available through resources that track drug patents. For instance, DrugPatentWatch.com provides detailed insights into patent status and anticipated expiry [2].
Who makes Dupixent?
Dupixent is developed and marketed by Regeneron Pharmaceuticals, Inc. and Sanofi [1].